FILTER

Refine your search with the following facets to narrow down your results.

22 Current news of PolyTherics

PolyTherics and Alpha Cancer Technologies Collaborate to Produce Drug Conjugates to Target Tumours

03-Jun-2014 - PolyTherics Limited, an Abzena company, announced a collaboration with Alpha Cancer Technologies Inc. (“ACT”. PolyTherics will produce a range of AFP drug conjugates for ACT to test using its proprietary ThioBridge™ technology.ACT has developed a drug delivery system based on AFP, a shuttle ...

cancer

PolyTherics and Antitope form Abzena

27-May-2014 - PolyTherics Limited announced the formation of a new company, Abzena Limited. The new company has been created to provide a strong group identity across its two wholly owned subsidiaries, PolyTherics and Antitope, following their combination in July 2013. During the summer PolyTherics’ operations ...

PolyTherics expands collaboration with a top five pharmaceutical company

17-Oct-2012 - PolyTherics Limited, a provider of solutions to enable the development of better biopharmaceuticals, has extended its collaboration with a top five pharmaceutical company to further investigate applications of PolyTherics’ polymer, PolyPEG®. PolyPEG™ is a patented polymer designed to extend the ...

biopharmaceuticals polymers proteins

PolyTherics Announces a Research Collaboration with Spirogen to Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

04-Apr-2012 - PolyTherics Limited announced that it has formed a research collaboration with Spirogen Limited to develop antibody-drug conjugates (ADCs) that combine PolyTherics’ proprietary site-specific conjugation chemistry with Spirogen’s highly potent novel cytotoxic drugs to produce novel ADCs for the ...

cancer

PolyTherics acquires Warwick Effect Polymers and expands technology portfolio to enable the development of better biopharmaceuticals

24-Jan-2012 - PolyTherics Limited announced the acquisition of Warwick Effect Polymers (“WEP”), a provider of specialty biopolymers for the modification of biological products. WEP has developed two proprietary biopolymer technologies, PolyPEG® and GlycoPol®, both of which are based on the leading academic ...

biopolymers

PolyTherics is granted a further patent for its TheraPEG PEGylation technology

09-Jun-2011 - PolyTherics Limited announced that a further patent has been issued by the US Patent Office for TheraPEG™, PolyTherics’ proprietary method of improving the pharmacokinetic properties of proteins and peptides. The patent consolidates PolyTherics’ TheraPEG™ patent portfolio, which covers proteins ...

patents PEGylation peptides +1

Keith Powell hands over to John Burt to lead PolyTherics

18-May-2011 - PolyTherics Limited announced that Dr Keith Powell, its Chief Executive Officer, will step down from the Board and as Chief Executive Officer on 25th May 2011 to pursue other interests.Keith joined PolyTherics in 2006 and has led the Company to a stage where it has a portfolio of commercial ...

PolyTherics and Critical Pharmaceuticals enter drug development collaboration with funding from the Technology Strategy Board

07-Apr-2011 - Critical Pharmaceuticals and PolyTherics Limited announced a collaboration to develop a novel injectable sustained release drug delivery system for a high value biological drug. The companies have been awarded a grant from the government-backed Technology Strategy Board to develop the technology ...

drug delivery

PolyTherics appoints Dr John Burt as Chief Business Officer

11-Nov-2010 - PolyTherics Limited announced the appointment of Dr John Burt as Chief Business Officer. John has broad business and corporate development experience and was previously CEO of Thiakis, a company which he co-founded with Professor Steve Bloom of Imperial College in 2004 and sold to Wyeth in ...

business development GSK Wyeth

PolyTherics to collaborate with UCL to develop a new treatment for ‘sticky blood’ syndrome

29-Sep-2010 - PolyTherics Limited announced a new collaboration with Professor Anisur Rahman at UCL (University College London), to use its proprietary site-specific PEGylation to develop a treatment for antiphospholipid syndrome. Professor Rahman and his team have been awarded a 5-year grant of nearly ...

antibodies anticoagulants arthritis +5